In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Incyte Corporation INCY, and raised its price target from $31.00 to $37.00.
Jefferies noted, “The FDA approved the Jak inhibitor Xeljanz (tofacitinib) as second-line therapy in moderate-severe rheumatoid arthritis patients. We believe this is a significant commercial positive for INCY's Jak inhibitor baricitinib, as Xeljanz is only approved for the lower dose (5mg), there is no label for structural improvements, and the Xeljanz price was much higher than we expected ($25k).”
Incyte Corporation closed on Tuesday at $17.71.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in